We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Large GWAS Pinpoints Ovarian Cancer Risk Genes

By LabMedica International staff writers
Posted on 13 May 2019
Print article
Image: A micrograph of a mucinous ovarian carcinoma (Photo courtesy of Wikimedia Commons).
Image: A micrograph of a mucinous ovarian carcinoma (Photo courtesy of Wikimedia Commons).
Results of a large genome-wide association study identified 34 genes that are associated with an increased risk for developing the earliest stages of ovarian cancer.

The current study, which was carried out by investigators at the University of California, Los Angeles (USA) and the Dana-Farber Cancer Institute (Boston, MA, USA), continued the assessment of large-scale genetic data that had been gathered over a period of more than 10 years by the Ovarian Cancer Association Consortium. Those investigators had found more than 30 regions in the genome associated with ovarian cancer after having compared the genetic profiles of about 25,000 women with ovarian cancer and 45,000 control subjects.

Applying advanced analytical tools, the current team of investigators identified 34 genes that were associated with an increased risk for developing ovarian cancer. Furthermore, this study implicated at least one target gene for six out of 13 distinct genome-wide association study regions and pinpointed 23 new candidate susceptibility genes for high-grade serous ovarian cancer.

"If you detect ovarian cancer really early, then the survival rate is very high, nearly 90% percent," said contributing author Dr. Bogdan Pasaniuc, associate professor of pathology and laboratory medicine at the University of California, Los Angles. "But that does not happen often. Most cases are found at a later stage and survival drops dramatically. That is why we want to understand the genetics behind it - so we can do a better job at predicting who is at a higher risk of developing this cancer."

"Whenever you inherit a piece of DNA from your parents, you do not inherit just every base pair of the genome, you inherit big chunks," said Dr. Pasanuic. "That means that if you inherit a gene mutation in a given region, you inherit the entire region, which can carry 10 to 20 genes at a time. This makes it very hard to pinpoint specific genes from specific regions. With the identification of these genes, we now have a narrow list of genes that can help us better predict ovarian cancer risks in women who may have never known that they were at a higher risk for developing the disease. While we are not there yet, we are hoping this study will lead to better outcomes because we will be able to monitor women earlier, when the cancer is easier to treat."

The ovarian cancer study was published in the May 1, 2019, online edition of the journal Nature Genetics.

Related Links:
University of California, Los Angeles
Dana-Farber Cancer Institute

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Luteinizing Hormone Assay
DRG LH-Serum ELISA Kit
New
Cytomegalovirus Test
NovaLisa Cytomegalovirus (CMV) IgG Test

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.